$4.00
3.15%
Nasdaq, Nov 14, 10:02 pm CET
Why the stock moved Why the stock moved Beta
ISIN
NL0015000DX5
Symbol
ATAI

ATAI Life Sciences N.V. Stock price

$4.00
-2.00 33.33% 1M
+2.57 179.72% 6M
+2.67 200.75% YTD
+2.63 191.97% 1Y
+1.15 40.35% 3Y
-15.45 79.43% 5Y
-15.45 79.43% 10Y
-15.45 79.43% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.13 3.15%
ISIN
NL0015000DX5
Symbol
ATAI
Industry

New AI Insights on ATAI Life Sciences N.V. Insights AI Insights on ATAI Life Sciences N.V.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.4b
Net debt
positive
Cash
$95.9m
Shares outstanding
212.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
628.9 | 564.2
EV/Sales
590.0 | 529.3
EV/FCF
negative
P/B
10.1
Financial Health
Equity Ratio
73.0%
Return on Equity
-128.4%
ROCE
-41.0%
ROIC
-76.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.3m | $2.6m
EBITDA
$-66.4m | $-99.8m
EBIT
$-67.1m | $-100.4m
Net Income
$-80.5m | $-108.1m
Free Cash Flow
$-81.8m
Growth (TTM | estimate)
Revenue
507.9% | 730.7%
EBITDA
38.4% | -0.5%
EBIT
37.9% | -0.7%
Net Income
-38.5% | 27.6%
Free Cash Flow
-3.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,869.2% | -3,876.0%
EBIT
-2,901.7%
Net
-3,476.5% | -4,199.4%
Free Cash Flow
-3,535.3%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
6.5%
Employees
54
Rev per Employee
$10.0k
Show more

Is ATAI Life Sciences N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

ATAI Life Sciences N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a ATAI Life Sciences N.V. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a ATAI Life Sciences N.V. forecast:

Buy
94%
Hold
6%

Financial data from ATAI Life Sciences N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2.31 2.31
508% 508%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
38% 38%
1,526%
- Research and Development Expense 34 34
33% 33%
1,481%
-66 -66
38% 38%
-2,874%
- Depreciation and Amortization 0.75 0.75
121% 121%
32%
EBIT (Operating Income) EBIT -67 -67
38% 38%
-2,907%
Net Profit -80 -80
39% 39%
-3,483%

In millions USD.

Don't miss a Thing! We will send you all news about ATAI Life Sciences N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ATAI Life Sciences N.V. Stock News

Positive
Proactive Investors
5 days ago
AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD) and other mental health conditions. During the quarter, the company's lead candidate BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray, was granted Breakthrough Therapy designation by the US ...
Positive
Proactive Investors
6 days ago
AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) is gaining analyst attention after Phase 2b results for its investigational therapy BPL-003 demonstrated rapid, meaningful, and durable antidepressant effects in treatment-resistant depression (TRD), reinforcing its potential as a differentiated psychedelic therapy. Jefferies highlighted that the data could influence dosing strategies and commercial positio...
Neutral
Seeking Alpha
6 days ago
Atai Beckley N.V. ( ATAI ) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST Company Participants Ashleigh Barreto Srinivas Rao - Co-Founder, CEO & Executive Director Kevin Craig - Chief Medical Officer Robert Conley - Chief Research & Development Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research ...
More ATAI Life Sciences N.V. News

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Head office Netherlands
CEO Dr. Rao
Employees 54
Founded 2018
Website atai.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today